Redirecting the fibroblast-immune conversation to develop impactful therapies for patients

Mestag is an immunology company driving first-in-class treatments for cancer and inflammatory diseases. Through our unique understanding of fibroblast biology, we are rapidly advancing a pipeline of sophisticated agonist antibody programs and exploring our RAFT target discovery platform to identify new targets for the development of new treatments. 

New approaches are urgently needed
We are working towards a future in which the 50-70 percent of cancer patients who fail to respond to current therapies, and the 60 percent of patients with inflammatory disease who fail to achieve durable clinical remission, can benefit from better treatments 1.

 

Impactful therapies for patients by redirecting fibroblast immunology

Mestag’s pipeline leverages powerful newly emerging fibroblast immunology, including the recently recognized importance of tertiary lymphoid structures (TLSs) in driving improved patient outcomes in solid tumors; and the role of stromal checkpoints in shutting down the pathogenic activity of selected immune cell populations in inflammatory disease.  

Lines
Susan Hill, PhD
Chief Executive Officer
Ray Jupp, PhD
Chief Scientific Officer
Andrew Joe, CMO Mestag Therapeutics
Andrew Joe, MD
Chief Medical Officer
Robert de Jonge, MSc
SVP, Head of Corporate Development
Eilidh Goodwin
Senior Director, Head of Finance
Ton Logtenberg, PhD
Chair
Susan Hill, MA, PhD
Chief Executive Officer
Charles Dunn, ACA
Kate Bingham, DBE
Fiona MacLaughlin, PhD
Issi Rozen, MBA
Diana Bernstein, PhD
Neil Weir, PhD
Antoine Boulanger, PhD
Michael B. Brenner, MD
Founder
Brigham and Women’s Hospital, Boston
Chris Buckley, MD
Founder
Kennedy Institute of Rheumatology, University of Oxford
Mark Coles, PhD
Founder
Kennedy Institute of Rheumatology, University of Oxford
Soumya Raychaudhuri, MD, PhD
Founder
Harvard Medical School
©Len Marks Photography, 2021/Cold Spring Harbor Laboratory
David A. Tuveson, MD, PhD
Founder
Cold Spring Harbor Laboratory, New York
Gabriele Bergers, PhD
Advisor
VIB Center for Cancer Biology and University of Leuven
Julie R. Brahmer, MD
Advisor
Johns Hopkins University School of Medicine
Jeffrey L. Browning, PhD
Advisor
Boston University School of Medicine
Greg Elson, PhD
Advisor
Wolf H. Fridman, MD
Advisor
Université Paris-Cité
Elizabeth M. Jaffee, MD
Advisor
Johns Hopkins University School of Medicine
Ignacio Melero, MD, PhD
Advisor
Academic Hospital and University of Navarra
Theresa Podrebarac, MD
Advisor
Catherine Sautès-Fridman, PhD
Advisor
Université Paris-Cité

Partners and Collaborators

MSD: Mestag has a license and research collaboration with MSD to identify novel targets for inflammatory diseases utilizing Mestag’s RAFT platform.

Janssen Biotech, Inc.:  Mestag entered into a target discovery collaboration with Janssen Biotech, Inc. The collaboration leverages Mestag’s specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets.

Innovate UK, part of UK Research and Innovation: Mestag received a “Transforming Cancer Therapeutics” grant from Innovate UK’s Cancer Therapeutics program of £1.5/$1.9 million to accelerate the path to the clinic for MST-0300.

VIB, an entrepreneurial research institute: Partnership for the development of single domain antibodies, also known as Nanobodies®, to an undisclosed target that plays a central role in anti-cancer immunity.

We also partner extensively with academic institutions worldwide and with leading CROs. For partnering discussions, please contact bd@mestagtx.com

Lines

Our Investors

References:
1) Internal 2020 analysis of ORR across 26 approved indications for checkpoint inhibitors (company sources, prescribing information); Wang et al., Sig Transduct Target Ther 2022; Hirsch et al., Br J Cancer 2019